Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.
24 juni, 23:42
Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.
PR Newswire
PHILADELPHIA, June 24, 2025
PHILADELPHIA , June 24, 2025 /PRNewswire/ -- Berger Montague , a nationally recognized securities litigation firm, is investigating potential claims on behalf of investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).
Hims & Hers headquartered in San Francisco, California , is a telehealth company that offers prescription treatments for weight loss, sexual health, mental health, and dermatology. Recently, the company expanded into the GLP-1 medication market, a class of drugs used to treat obesity and type 2 diabetes, including semaglutide, the active ingredient in Wegovy® and Ozempic®, developed by Novo Nordisk.
On June 23, 2025 , Novo Nordisk announced the termination of its partnership with Hims & Hers, alleging that the company engaged in deceptive marketing and sold unapproved compounded versions of semaglutide. Following the announcement, shares of Hims & Hers declined by over 26% in intraday trading, reflecting investor concerns regarding regulatory compliance and reputational risks.
Berger Montague's investigation focuses on whether Hims & Hers and certain officers and directors made materially false or misleading statements or omitted material information regarding the nature and regulatory status of its GLP-1 offerings, the associated risks, and the partnership with Novo Nordisk.
If you are a Hims & Hers investor and would like to learn more about our investigation, CLICK HERE or please contact Berger Montague : Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Peter Hamner at phamner@bm.net .
About Berger Montague
Berger Montague , with offices in Philadelphia , Minneapolis , Delaware , Washington, D.C. , San Diego , San Francisco and Chicago , has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States .
For more information or to discuss your rights, please contact:
Andrew Abramowitz , Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net
Peter Hamner
Berger Montague PC
phamner@bm.net
SOURCE Berger Montague
Ämnen i artikeln
Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.
24 juni, 23:42
Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.
PR Newswire
PHILADELPHIA, June 24, 2025
PHILADELPHIA , June 24, 2025 /PRNewswire/ -- Berger Montague , a nationally recognized securities litigation firm, is investigating potential claims on behalf of investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).
Hims & Hers headquartered in San Francisco, California , is a telehealth company that offers prescription treatments for weight loss, sexual health, mental health, and dermatology. Recently, the company expanded into the GLP-1 medication market, a class of drugs used to treat obesity and type 2 diabetes, including semaglutide, the active ingredient in Wegovy® and Ozempic®, developed by Novo Nordisk.
On June 23, 2025 , Novo Nordisk announced the termination of its partnership with Hims & Hers, alleging that the company engaged in deceptive marketing and sold unapproved compounded versions of semaglutide. Following the announcement, shares of Hims & Hers declined by over 26% in intraday trading, reflecting investor concerns regarding regulatory compliance and reputational risks.
Berger Montague's investigation focuses on whether Hims & Hers and certain officers and directors made materially false or misleading statements or omitted material information regarding the nature and regulatory status of its GLP-1 offerings, the associated risks, and the partnership with Novo Nordisk.
If you are a Hims & Hers investor and would like to learn more about our investigation, CLICK HERE or please contact Berger Montague : Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Peter Hamner at phamner@bm.net .
About Berger Montague
Berger Montague , with offices in Philadelphia , Minneapolis , Delaware , Washington, D.C. , San Diego , San Francisco and Chicago , has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States .
For more information or to discuss your rights, please contact:
Andrew Abramowitz , Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net
Peter Hamner
Berger Montague PC
phamner@bm.net
SOURCE Berger Montague
Ämnen i artikeln
-992x558.webp&w=3840&q=75)
Aktierekommendationer
Analyser
-160x160.jpg&w=3840&q=75)
Oljepriset
-992x558.png&w=3840&q=75)
.jpg&w=3840&q=75)
Mest läst
Aktierekommendationer
Analyser
Oljepriset
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
